View this email in your browser

ttps://gallery.mailchimp.com/8916ce2925b89c16fd9d14172/images/fa24a219-94c5-4a9b-b013-5f4d4de2f4ee.png
ABOUT ADAPTIVE BIOTECHNOLOGIES  

____

As a pioneer and leader in the field of immunosequencing, Adaptive Biotechnologies combines next generation sequencing (NGS) and proprietary bioinformatics to profile T-cell and B-cell receptors to drive groundbreaking research in cancer and other immune-mediated diseases.


ABOUT MINIMAL RESIDUAL DISEASE (MRD)
____

MRD is increasingly being used to inform treatment decisions, making MRD test selection increasingly important.

  • Minimal, or measurable, residual disease (MRD) refers to the small number of cancer cells that can remain in a patient’s body during and after treatment, often causing no physical signs or symptoms, and that may result in disease recurrence.
  • With the variety of new treatment options that are becoming available for blood cancer patients, clinicians are eager to have as much information as possible to help them decide the most appropriate course for each patient.
  • What we are seeing is a shift in which MRD is replacing traditional primary endpoints such as progression-free survival (PFS) in clinical trials.1
  • As technologies for MRD detection have improved, physicians have been able to detect increasingly smaller amounts of disease, and in myeloma for example, controlled trials have shown that even these small amounts of disease matter when it comes to predicting a patient’s long-term clinical outcomes.2
  • Selection of an appropriate MRD test becomes even more important when you consider clinicians now have access to an approved, MRD-directed therapy.3

MRD testing is an essential component of clinical practice guidelines for lymphoid malignancies like multiple myeloma and acute lymphoblastic leukemia (ALL).

  • For myeloma patients, the NCCN® Guidelines and IMWG Consensus Criteria recommend MRD assessment using a validated assay after each treatment stage.4,5
  • For ALL patients, the NCCN® Guidelines recommend MRD assessment after completion of initial induction and at additional time points depending on treatment regimen. The guidelines also call for baseline characterization of the leukemic clone to facilitate subsequent MRD analysis.6

 

 

ttps://gallery.mailchimp.com/8916ce2925b89c16fd9d14172/images/b53d1b37-ddd3-4eb1-a642-f30ef4dcb069.png
ABOUT THE CLONOSEQ
® ASSAY
____

clonoSEQ, is a highly-accurate, sensitive, and standardized MRD test to help predict patient outcomes, assess treatment response, monitor disease burden over time, and detect signs of returning disease.
2,7,8,9,10

  • clonoSEQ is a next-generation sequencing (NGS)-powered test that detects, quantifies, and monitors MRD in patients with lymphoid malignancies like multiple myeloma and ALL.2,11
  • Using the unique DNA sequences that are associated with lymphocyte receptors for a specific patient, clonoSEQ precisely identifies malignant cells, counts how many of those cells are present in a patient’s bone marrow sample, and then tracks those cancer cells over time.6,12
  • clonoSEQ testing is already being used at the majority of NCCN cancer centers (24 of 27) and usage is expanding to referral centers and community practices.

clonoSEQ is the first and only FDA-cleared test for MRD assessment in any lymphoid cancer.

  • clonoSEQ has received FDA clearance as an in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies for use in B-cell ALL and multiple myeloma patients to detect and monitor MRD in bone marrow samples. clonoSEQ is also available for use in other lymphoid cancers as a CLIA-regulated laboratory developed test (LDT) service provided by Adaptive Biotechnologies.
  • clonoSEQ results should always be used in combination with clinical examination, patient medical history, and other findings. Results may vary according to sample time within the course of disease or by sampling site location.
  • For important information about the FDA-cleared uses of clonoSEQ, including test limitations, visit clonoSEQ.com/technical-summary

 

 

1. Clinicaltrials.gov search. Outcome measure: minimal residual disease. 2018.
2. Martinez-Lopez J, et al. Blood. 2014;123(20):3073-3079.
3. FDA; (2018). FDA expands approval of Blincyto for treatment of a type of leukemia in patients who have a certain risk factor for relapse. [online] Available at: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm603151.htm [Accessed 7 July 2018].
4. NCCN Clinical Practice Guidelines in Oncology®: Multiple Myeloma. Version 1.2019.

5. Kumar S, at al. Lancet Oncol. 2016;17(8):e328-46.

6. NCCN Clinical Practice Guidelines in Oncology®: Acute Lymphoblastic Leukemia. Version 1.2018.
7. Faham M, et al. Blood. 2012;120(26):5173-80. (study author was an employee of Adaptive at time of publishing)
8. Data on file. Adaptive Biotechnologies. 2018.
9. Pulsipher M, et al. Blood. 2015;125(22):3501-8.
10. Korde N, et al. JAMA Oncol. 2015;1(6):746-54.
11. Wood B, et al. Blood. 2018;131(12):1350-9.
12. Carlson C, et al. Nat Commun. 2013;4:2680. (Research studies were supported, in part, by Adaptive Biotechnologies)